These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 16140944

  • 1. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.
    Cancer Res; 2005 Sep 01; 65(17):7763-74. PubMed ID: 16140944
    [Abstract] [Full Text] [Related]

  • 2. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
    Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS.
    Oncogene; 2007 Jun 28; 26(30):4394-403. PubMed ID: 17260018
    [Abstract] [Full Text] [Related]

  • 3. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.
    Cancer Res; 2005 Sep 01; 65(17):7751-62. PubMed ID: 16140943
    [Abstract] [Full Text] [Related]

  • 4. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
    Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA.
    Cancer Res; 2002 Jul 15; 62(14):3971-9. PubMed ID: 12124329
    [Abstract] [Full Text] [Related]

  • 5. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
    Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.
    J Cell Biochem; 2006 Aug 01; 98(5):1037-43. PubMed ID: 16741971
    [Abstract] [Full Text] [Related]

  • 6. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.
    J Natl Cancer Inst; 2006 Mar 15; 98(6):396-406. PubMed ID: 16537832
    [Abstract] [Full Text] [Related]

  • 7. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis.
    Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T, Ushijima T.
    Oncogene; 2001 Nov 08; 20(51):7505-13. PubMed ID: 11709722
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
    Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert E, St Clair F, Old LJ, Cebon J.
    Clin Cancer Res; 2004 Dec 15; 10(24):8396-404. PubMed ID: 15623618
    [Abstract] [Full Text] [Related]

  • 9. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L, Wang RF, Wang X, Mixon A, Johnson BE, Rosenberg SA, Schrump DS.
    Cancer J Sci Am; 1999 Dec 15; 5(1):20-5. PubMed ID: 10188057
    [Abstract] [Full Text] [Related]

  • 10. Hypermethylation of the GATA genes in lung cancer.
    Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV.
    Clin Cancer Res; 2004 Dec 01; 10(23):7917-24. PubMed ID: 15585625
    [Abstract] [Full Text] [Related]

  • 11. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
    Wang XY, Chen HS, Luo S, Zhang HH, Fei R, Cai J.
    Oncol Rep; 2009 Mar 01; 21(3):713-9. PubMed ID: 19212631
    [Abstract] [Full Text] [Related]

  • 12. Transcriptional regulator CTCF controls human interleukin 1 receptor-associated kinase 2 promoter.
    Kuzmin I, Geil L, Gibson L, Cavinato T, Loukinov D, Lobanenkov V, Lerman MI.
    J Mol Biol; 2005 Feb 18; 346(2):411-22. PubMed ID: 15670593
    [Abstract] [Full Text] [Related]

  • 13. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
    Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T.
    Int J Oncol; 2006 May 18; 28(5):1089-98. PubMed ID: 16596224
    [Abstract] [Full Text] [Related]

  • 14. Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.
    Pugacheva EM, Tiwari VK, Abdullaev Z, Vostrov AA, Flanagan PT, Quitschke WW, Loukinov DI, Ohlsson R, Lobanenkov VV.
    Hum Mol Genet; 2005 Apr 01; 14(7):953-65. PubMed ID: 15731119
    [Abstract] [Full Text] [Related]

  • 15. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, Doki Y, Yasui M, Sugita Y, Yasuda T, Yano M, Ono T, Chen YT, Higashiyama M, Gnjatic S, Old LJ, Nakayama E, Monden M.
    Clin Cancer Res; 2004 Oct 01; 10(19):6551-8. PubMed ID: 15475443
    [Abstract] [Full Text] [Related]

  • 16. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ.
    Cancer Res; 2003 Sep 15; 63(18):6076-83. PubMed ID: 14522938
    [Abstract] [Full Text] [Related]

  • 17. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
    Stirzaker C, Song JZ, Davidson B, Clark SJ.
    Cancer Res; 2004 Jun 01; 64(11):3871-7. PubMed ID: 15172996
    [Abstract] [Full Text] [Related]

  • 18. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.
    Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, Bagella L, Giordano A.
    Mol Cancer Res; 2011 Feb 01; 9(2):225-33. PubMed ID: 21325284
    [Abstract] [Full Text] [Related]

  • 19. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R.
    Carcinogenesis; 2004 May 01; 25(5):693-701. PubMed ID: 14729589
    [Abstract] [Full Text] [Related]

  • 20. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.
    Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK.
    Clin Cancer Res; 2005 Nov 15; 11(22):8055-62. PubMed ID: 16299236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.